Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.
17 Maio 2023 - 5:01PM
Business Wire
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical
company dedicated to the development of innovative therapeutics to
treat seizure disorders, today announced the appointment of Sarah
Noonberg, M.D., Ph.D., to its Board of Directors.
“Sarah is an accomplished healthcare executive with extensive
global clinical development and corporate strategy experience,”
said Scott Braunstein, M.D., Chairman and Chief Executive Officer
of Marinus. “With a track record of successfully advancing programs
in various therapeutic areas using diverse modalities, a deep
understanding of orphan diseases and over a decade of experience as
a hospitalist physician, her unique perspective will be invaluable
to our strategic decision-making as we shape our organization's
future and evaluate opportunities to expand our pipeline into other
rare epilepsy disorders.”
Dr. Noonberg is a physician-scientist with a diverse background
in translational science, clinical development, medical affairs and
corporate governance. She has significant experience designing and
leading rare disease programs from discovery to global regulatory
approvals and commercialization. Dr. Noonberg currently serves as
the Chief Medical Officer of Metagenomi, a privately held genomics
company, where she is advancing its gene editing technology
platform toward the clinic. She previously served as Chief Medical
Officer of Maze Therapeutics, Nohla Therapeutics and Prothena
Biosciences and prior to that, held clinical development executive
leadership roles at BioMarin and at Medivation. Her industry
experience is complemented by more than 10 years of experience
treating patients as a hospitalist physician.
“Marinus has emerged as a leader in the development of
innovative treatment options for patients with genetic epilepsies
and seizure disorders. With a passion for innovation and improving
clinical outcomes for patients with rare diseases, I look forward
to working with the Marinus team to advance the company’s current
and future goals,” said Sarah Noonberg, M.D., Ph.D.
Dr. Noonberg currently serves on the Board of Directors at
Protagonist Therapeutics and Neoleukin Therapeutics. She trained in
internal medicine at Johns Hopkins Hospital, received an M.D. from
the University of California, San Francisco, a Ph.D. in
bioengineering from the University of California, Berkeley, and a
bachelor’s degree in engineering science from Dartmouth
College.
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated
to the development of innovative therapeutics for seizure
disorders. The Company’s commercial product, ZTALMY® (ganaxolone)
oral suspension CV, has been approved by the U.S. FDA for the
treatment of seizures associated with CDKL5 deficiency disorder in
patients two years of age and older. The potential of ganaxolone is
also being studied in other rare seizure disorders, including in
Phase 3 trials in tuberous sclerosis complex and refractory status
epilepticus. Ganaxolone is a neuroactive steroid GABAA receptor
modulator that acts on a well-characterized target in the brain
known to have anti-seizure effects. It is being developed in IV and
oral formulations to maximize therapeutic reach for adult and
pediatric patients in acute and chronic care settings. For more
information visit www.marinuspharma.com.
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Marinus, they
are forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Words such as "may", "will", "expect", "anticipate", "estimate",
"intend", "believe", and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
Examples of forward-looking statements contained in this press
release include, among others, our commercial and clinical
strategy, development plans and timelines, and other future
events.
Forward-looking statements in this press release involve
substantial risks and uncertainties that could cause our clinical
development programs, future results, performance or achievements
to differ significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, unexpected market acceptance, payor coverage or
future prescriptions and revenue generated by ZTALMY; unexpected
actions by the FDA or other regulatory agencies with respect to our
products; competitive conditions and unexpected adverse events or
patient outcomes from being treated with ZTALMY, uncertainties and
delays relating to the design, enrollment, completion, and results
of clinical trials; unanticipated costs and expenses; the company’s
cash and cash equivalents may not be sufficient to support its
operating plan for as long as anticipated; our ability to comply
with the FDA’s requirement for additional post-marketing studies in
the required time frames; the timing of regulatory filings for our
other product candidates; clinical trial results may not support
regulatory approval or further development in a specified
indication or at all; actions or advice of the FDA or EMA may
affect the design, initiation, timing, continuation and/or progress
of clinical trials or result in the need for additional clinical
trials; the size and growth potential of the markets for the
company’s product candidates, and the company’s ability to service
those markets; the company’s expectations, projections and
estimates regarding expenses, future revenue, capital requirements,
and the availability of and the need for additional financing;
delays, interruptions or failures in the manufacture and supply of
our product candidates; the company’s ability to obtain additional
funding to support its clinical development and commercial
programs; and the effect of the COVID-19 pandemic on our business,
the medical community, regulators and the global economy. This list
is not exhaustive and these and other risks are described in our
periodic reports, including our annual reports on Form 10-K,
quarterly reports on Form 10-Q and current reports on Form 8-K,
filed with or furnished to the Securities and Exchange Commission
and available at www.sec.gov. Any forward-looking statements that
we make in this press release speak only as of the date of this
press release. We assume no obligation to update forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230517005563/en/
Sasha Damouni Ellis Senior Vice President, Corporate Affairs
& Investor Relations Marinus Pharmaceuticals, Inc.
sdamouni@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024